Table 2.
Study population
| Presenting at ER | Presenting at outpatient clinic n = 53 | |
|---|---|---|
| n = 230 | ||
| Sex, male (n, %) | 126 (54.8%) | 35 (66.0%) |
| Age, years (median, range) | 67.0 (18‐95) | 57 (19‐81) |
| Underlying illness * | 190 (82.6%) | 49 (92.5%) |
| Respiratory viruses detected | ||
| Influenza A | 77 (33.5%) | 9 (17.0%) |
| Influenza B | 1 (0.4%) | 1 (1.9%) |
| RSV | 13 (5.7%) | 6 (11.3%) |
| Negative | 128 (55.7%) | 26 (49.1%) |
| Influenza + RSV | ‐ | 1 (1.9%) |
| Other respiratory virus | 11 (4.8%) | 10 (18.9%) |
| Admission | 197 (85.7%) | 20 (37.7%) |
| ICU admission | 38 (19.2%) | 2 (10.0%) |
| Length of stay, days (median, range) | 6.0 (0‐58) | 6.0 (2‐22) |
| Isolated care | 171 (86.8%) | 16 (80.0%) |
| Time until diagnosis * , days (median, range) | 1.0 (0‐3) | 1.0 (1‐4) |
| Antiviral use | ||
| Yes | 85 (37.0%) | 7 (13.2%) |
| Duration, days (median, range) | 4.0 (0‐10) | 5.0 (1‐10) |
| Initiated but influenza negative | 41 (48.2%) | 4 (57.1%) |
| Duration if influenza negative, days (median, range) | 1.0 (0‐5) | 2.0 (1‐6) |
| Duration if influenza positive, days (median, range) | 5.0 (3‐10) * | 7.0 (5‐10) |
| Antibiotic use | ||
| Yes | 166 (72.2%) | 29 (54.7%) |
| Duration, days (median, range) | 6.0 (0‐19) | 7.0 (1‐10) |
| Duration if influenza or RSV positive, days (median, range) | 4.0 (0‐14) * | 7.0 (1‐10) |
| Duration if influenza or RSV negative, days (median, range) | 7.0 (0‐19) | 7.0 (3‐10) |
Abbreviation: RSV, respiratory syncytial virus.
*
hematological malignancy, COPD and other pulmonary diseases, diabetes, oncology.
§
time between sample collection and result of routine respiratory PCR.
≠
P < 0.001 compared with influenza or RSV negative.
This article is being made freely available through PubMed Central as part of the COVID-19 public health emergency response. It can be used for unrestricted research re-use and analysis in any form or by any means with acknowledgement of the original source, for the duration of the public health emergency.